Lithium Carbonate Modulation of Delayed Rectifier Potassium Channel Involves Protein Kinase C/Mitogen-Activated Protein Kinase Signaling in Hippocampus of Rats

Jiao Guo-Hui,Liu Zhao-Wei,Zhang Tao,Yang Zhuo
DOI: https://doi.org/10.3321/j.issn:1000-3282.2008.07.013
2008-01-01
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
Abstract:Lithium carbonate could be used to treat or prevent brain damage following traumatic injury and neurodegenerative diseases. It has been shown that its protective effect is related to protein kinase C (PKC) and extracellular signal-related kinase (ERK). It was demonstrated that PDBu, a PKC activator, inhibited amplitudes of delayed rectifier potassium current (I-K) and produced a hyperpolarizing shift in the activation-voltage curve. The responses to PDBu were inhibited by lithium carbonate (50 mu mol/L). Further studies showed that when pretreated with MEK/ERK inhibitor U0126 (20 mu mol/L), although PDBu significantly reduced I-K, lithium did not reverse the effect of PDBu. Thus, the results suggested that PKC signaling cascades, along with MAPK (mitogen-activated protein kinase) pathway, were required in the phosphorylation of potassium channel, which was presented by regulation of potassium channel characteristic. AC-cAMP and their cross-talk with GC-cGMP pathway could also modulate the effect of lithium on PKC activation, which could be one of underlying mechanisms likely related to neuroprotective effect of lithium.
What problem does this paper attempt to address?